Authors

Tanios S. Bekaii-Saab, MD, is the leader of the Gastrointestinal Cancer Program at the Mayo Clinic Comprehensive Cancer Center; as well as medical director of the Cancer Clinical Research Office and vice chair and section chief for Medical Oncology in the Department of Internal Medicine at Mayo Clinic

Latest:

Dr Bekaii-Saab on Evolving Sequencing Approaches in CRC

Tanios S. Bekaii-Saab, MD, discusses sequencing decisions according to molecular subgroups in colorectal cancer.

Tanios S. Bekaii-Saab, MD, FACP

Latest:

Nivolumab plus Ipilimumab vs Chemotherapy as First-line Treatment for Microsatellite Instability-High/Mismatch Repair Deficient Metastatic Colorectal Cancer: First Results of the CheckMate 8HW Study

In his discussion of the CHECKMATE 8HW trial, Dr. Tanios Bekaii-Saab examined the efficacy of chemotherapy versus nivolumab plus ipilimumab as the initial treatment for metastatic colorectal cancer with high microsatellite instability and deficient mismatch repair.

Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic

Latest:

Metastatic Colorectal Cancer: Ongoing Challenges and Future Directions in Care

Closing out their panel on metastatic colorectal cancer, expert oncologists consider ongoing challenges and future evolutions within the treatment landscape.

Tanios S. Bekaii-Saab, MD, Mayo Clinic

Latest:

Real-World Use of HER2-Directed Therapies in Colorectal Cancers

Expert perspectives on the real-world use of HER2-directed therapies in patients with HER2-amplified colorectal cancer.

Tanios S. Bekaii-Saab, MD, Mayo Clinic Cancer Center

Tannaz Armaghany, MD

Latest:

Dr. Armaghany on the Utility of ctDNA in CRC

Tannaz Armaghany, MD, discusses the utility of circulating tumor DNA in colorectal cancer.

Tanya B. Dorff, MD

Tanya B. Dorff, MD, is section chief of the Genitourinary Disease Program and professor in the Department of Medical Oncology and Therapeutics Research at City of Hope in Duarte, California.

Latest:

Safety and Quality-of-Life Considerations Shape ADT Use in Prostate Cancer: With Tanya B. Dorff, MD

Dr Dorff discusses the role of ADT in prostate cancer management, how this class has evolved, and the use of relugolix across treatment settings.

Tanya Dorff, MD, City of Hope Comprehensive Cancer Center

Latest:

ASCO 2020: Updates in Prostate Cancer Treatment

Tanya Dorff, MD, City of Hope National Medical Center

Tanya M. Wildes, MD, MSCI

Latest:

New Geriatric Assessment Tools Enhance Care of Older Adults with Cancer

Amid a coming storm of demographic trends signaling a sharp increase in the number of older people diagnosed with cancer in the United States, researchers are developing new geriatric assessment tools to help oncology specialists better manage this patient population.

Tanya Siddiqi, MD

Latest:

Dr. Siddiqi on the Role of Acalabrutinib in Frontline CLL

Tanya Siddiqi, MD, discusses the role of acalabrutinib as a frontline treatment for patients with chronic lymphocytic leukemia.

Taofeek K. Owonikoko, MD, PhD

Latest:

Dr Owonikoko on the Impact of the FDA Approval of Tarlatamab in ES-SCLC

Taofeek Owonikoko, MD, PhD, expands on the FDA approval of tarlatamab for patients with extensive-stage small cell lung cancer.

Taofeek K. Owonikoko, MD, PhD; UPMC Hillman Cancer Center

Latest:

Novel Treatment Approaches for SCLC and Future Perspectives

A panel of expert oncologists offer closing thoughts on the future treatment landscape and unmet needs in small-cell lung cancer.

Tapan A. Padhya, MD

Latest:

Prognostic Significance of Post-Treatment PET/CT Following Salvage Re-irradiation of Head and Neck Cancers

Researchers explored the prognostic significance of PET/CT following re-irradiation in patients with head and neck cancer.

Tara C. Mitchell, MD

Latest:

Dr. Gangadhar on Combination Regimens for Melanoma

Tara C. Mitchell, MD, assistant professor of Medicine, Perelman School of Medicine at the Hospital of the University of Pennsylvania, discusses new combination regimens for patients with melanoma.

Tara E. Seery, MD, UC Irvine

Tara Graff, DO, MS, Mission Cancer + Blood

Latest:

Looking Toward the Future of CLL Management

An expert hematologist/oncologist highlights key takeaways for the future management of chronic lymphocytic leukemia given an evolving therapeutic landscape.

Tara Petersen

Latest:

Neuroendocrine Tumor Treatment Options Are Growing

During the past several years, a wealth of positive clinical trials coupled with an evolution in understanding of neuroendocrine tumors has altered the treatment landscape.

Tara Sanft, MD

Latest:

Dr. Sanft on Sequencing of Treatments for HER2+ Breast Cancer

Tara Sanft, MD, assistant professor of Medicine, medical director of Adult Survivorship for Yale Cancer Center Survivorship Clinic, discusses sequencing of treatments for patients with HER2-positive breast cancer.

Tari King, MD, FACS

Latest:

Dr. King on Neoadjuvant Chemotherapy in Breast Cancer

Tari King, MD, FACS, chief of Breast Surgery, Dana-Farber Cancer Institute, Brigham Womens Cancer Center, discusses the role of a multidisciplinary team when considering neoadjuvant chemotherapy (NAC) for patients with breast cancer.